Concepts (226)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Anesthesia, General | 8 | 2020 | 30 | 2.400 |
Why?
|
| Anesthesia | 5 | 2014 | 25 | 1.650 |
Why?
|
| Anesthesiology | 4 | 2012 | 18 | 1.300 |
Why?
|
| Intubation, Intratracheal | 2 | 2014 | 26 | 0.790 |
Why?
|
| Multiple Endocrine Neoplasia Type 2b | 1 | 2020 | 1 | 0.710 |
Why?
|
| Neuroma | 1 | 2020 | 5 | 0.710 |
Why?
|
| Pheochromocytoma | 1 | 2020 | 9 | 0.710 |
Why?
|
| Adrenal Gland Neoplasms | 1 | 2020 | 15 | 0.700 |
Why?
|
| Thyroid Neoplasms | 1 | 2020 | 37 | 0.680 |
Why?
|
| Pediatrics | 2 | 2012 | 87 | 0.640 |
Why?
|
| Reflex Sympathetic Dystrophy | 1 | 2017 | 3 | 0.570 |
Why?
|
| Secondary Prevention | 1 | 2017 | 44 | 0.560 |
Why?
|
| Patient Positioning | 1 | 2017 | 22 | 0.560 |
Why?
|
| Neural Tube Defects | 1 | 2017 | 19 | 0.560 |
Why?
|
| Ventriculoperitoneal Shunt | 1 | 2017 | 26 | 0.550 |
Why?
|
| Cesarean Section | 1 | 2017 | 55 | 0.540 |
Why?
|
| Parents | 2 | 2014 | 121 | 0.530 |
Why?
|
| Acetaminophen | 1 | 2015 | 11 | 0.500 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2015 | 8 | 0.490 |
Why?
|
| Medication Errors | 1 | 2015 | 26 | 0.490 |
Why?
|
| Uncertainty | 1 | 2014 | 23 | 0.470 |
Why?
|
| Humans | 31 | 2024 | 26828 | 0.460 |
Why?
|
| Health Education | 1 | 2014 | 71 | 0.440 |
Why?
|
| Anxiety | 1 | 2014 | 139 | 0.430 |
Why?
|
| Child | 11 | 2021 | 2146 | 0.410 |
Why?
|
| Heart Arrest | 2 | 2010 | 26 | 0.390 |
Why?
|
| Male | 19 | 2020 | 12868 | 0.370 |
Why?
|
| Magnetic Resonance Imaging | 3 | 2020 | 801 | 0.370 |
Why?
|
| Hypercapnia | 1 | 2010 | 5 | 0.370 |
Why?
|
| Anesthesia, Closed-Circuit | 1 | 2010 | 3 | 0.370 |
Why?
|
| Child, Preschool | 10 | 2014 | 1090 | 0.370 |
Why?
|
| Attitude of Health Personnel | 1 | 2012 | 139 | 0.370 |
Why?
|
| Equipment Failure | 1 | 2010 | 31 | 0.360 |
Why?
|
| Glycogen Storage Disease Type IV | 1 | 2010 | 1 | 0.360 |
Why?
|
| Diagnostic Errors | 2 | 2008 | 33 | 0.330 |
Why?
|
| Optical Fibers | 1 | 2009 | 5 | 0.330 |
Why?
|
| Neck | 1 | 2009 | 25 | 0.330 |
Why?
|
| Lighting | 1 | 2009 | 9 | 0.330 |
Why?
|
| Burns | 1 | 2009 | 16 | 0.320 |
Why?
|
| Infant | 9 | 2012 | 957 | 0.320 |
Why?
|
| Propofol | 2 | 2006 | 10 | 0.320 |
Why?
|
| Hyperkalemia | 1 | 2008 | 8 | 0.320 |
Why?
|
| Head Injuries, Penetrating | 1 | 2008 | 4 | 0.320 |
Why?
|
| Renal Insufficiency | 1 | 2008 | 20 | 0.320 |
Why?
|
| Foreign Bodies | 1 | 2008 | 16 | 0.310 |
Why?
|
| Catheterization, Peripheral | 1 | 2008 | 24 | 0.310 |
Why?
|
| Abnormalities, Multiple | 1 | 2008 | 34 | 0.300 |
Why?
|
| Pneumothorax, Artificial | 1 | 2006 | 1 | 0.270 |
Why?
|
| Health Status | 1 | 2007 | 145 | 0.270 |
Why?
|
| Mediastinal Neoplasms | 1 | 2006 | 11 | 0.270 |
Why?
|
| Methemoglobinemia | 1 | 2005 | 2 | 0.260 |
Why?
|
| Rosaniline Dyes | 1 | 2005 | 8 | 0.260 |
Why?
|
| Coloring Agents | 1 | 2005 | 33 | 0.260 |
Why?
|
| Infusion Pumps | 1 | 2005 | 3 | 0.260 |
Why?
|
| Pulmonary Embolism | 1 | 2006 | 126 | 0.240 |
Why?
|
| Kidney Failure, Chronic | 1 | 2024 | 68 | 0.220 |
Why?
|
| Brain | 1 | 2008 | 698 | 0.210 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 4 | 2006 | 36 | 0.210 |
Why?
|
| Anesthesia, Epidural | 1 | 2022 | 7 | 0.200 |
Why?
|
| Analgesia | 1 | 2021 | 12 | 0.190 |
Why?
|
| Anesthetics, Local | 1 | 2021 | 12 | 0.190 |
Why?
|
| Female | 9 | 2017 | 14456 | 0.180 |
Why?
|
| Infant, Newborn | 2 | 2017 | 844 | 0.170 |
Why?
|
| Spinal Puncture | 3 | 2006 | 11 | 0.170 |
Why?
|
| Pain, Postoperative | 2 | 2021 | 59 | 0.150 |
Why?
|
| Single-Blind Method | 2 | 2014 | 43 | 0.150 |
Why?
|
| Equipment and Supplies, Hospital | 1 | 2017 | 2 | 0.140 |
Why?
|
| Supine Position | 1 | 2017 | 4 | 0.140 |
Why?
|
| Sodium Channels | 2 | 2006 | 8 | 0.140 |
Why?
|
| Treatment Outcome | 3 | 2024 | 2262 | 0.140 |
Why?
|
| Renal Dialysis | 2 | 2024 | 52 | 0.140 |
Why?
|
| Elective Surgical Procedures | 1 | 2017 | 70 | 0.140 |
Why?
|
| Adult | 3 | 2021 | 7381 | 0.130 |
Why?
|
| Nose | 1 | 2014 | 22 | 0.120 |
Why?
|
| Video Recording | 1 | 2014 | 38 | 0.120 |
Why?
|
| Language | 1 | 2014 | 62 | 0.110 |
Why?
|
| Barbiturates | 1 | 1993 | 1 | 0.110 |
Why?
|
| Carbachol | 1 | 1993 | 18 | 0.110 |
Why?
|
| Receptors, Cholinergic | 1 | 1993 | 4 | 0.110 |
Why?
|
| Prospective Studies | 2 | 2014 | 1216 | 0.110 |
Why?
|
| Myoclonus | 1 | 1993 | 2 | 0.110 |
Why?
|
| Logistic Models | 1 | 2014 | 397 | 0.110 |
Why?
|
| Morphine | 1 | 1993 | 28 | 0.110 |
Why?
|
| Adolescent | 3 | 2021 | 2955 | 0.110 |
Why?
|
| Pregnancy | 1 | 2017 | 1130 | 0.110 |
Why?
|
| Pilot Projects | 1 | 2014 | 390 | 0.100 |
Why?
|
| Succinylcholine | 2 | 2008 | 3 | 0.100 |
Why?
|
| Clinical Competence | 2 | 2012 | 204 | 0.100 |
Why?
|
| Drug Administration Routes | 1 | 2012 | 8 | 0.100 |
Why?
|
| Bedding and Linens | 1 | 2012 | 2 | 0.100 |
Why?
|
| Lambert-Eaton Myasthenic Syndrome | 1 | 1992 | 1 | 0.100 |
Why?
|
| Heating | 1 | 2012 | 6 | 0.100 |
Why?
|
| Neoplasms, Unknown Primary | 1 | 1992 | 8 | 0.100 |
Why?
|
| Hypothermia | 1 | 2012 | 6 | 0.100 |
Why?
|
| Carcinoma, Small Cell | 1 | 1992 | 14 | 0.100 |
Why?
|
| Calcium Channels | 1 | 1992 | 32 | 0.100 |
Why?
|
| Surveys and Questionnaires | 2 | 2012 | 917 | 0.090 |
Why?
|
| Carbon Dioxide | 1 | 2010 | 85 | 0.090 |
Why?
|
| Ganglia, Spinal | 2 | 2006 | 25 | 0.090 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2010 | 33 | 0.090 |
Why?
|
| Age Factors | 1 | 2012 | 716 | 0.080 |
Why?
|
| Lactic Acid | 1 | 2010 | 89 | 0.080 |
Why?
|
| Oxygen | 1 | 2010 | 217 | 0.080 |
Why?
|
| Xenon | 1 | 2009 | 1 | 0.080 |
Why?
|
| Equipment Safety | 1 | 2009 | 18 | 0.080 |
Why?
|
| Autoantibodies | 1 | 1992 | 466 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2006 | 151 | 0.080 |
Why?
|
| Blood Glucose | 1 | 2010 | 300 | 0.080 |
Why?
|
| Neuromuscular Depolarizing Agents | 1 | 2008 | 2 | 0.080 |
Why?
|
| Posture | 1 | 2008 | 39 | 0.080 |
Why?
|
| Oklahoma | 1 | 2012 | 973 | 0.080 |
Why?
|
| Syndrome | 1 | 2008 | 78 | 0.080 |
Why?
|
| American Medical Association | 1 | 2007 | 3 | 0.070 |
Why?
|
| Lung Neoplasms | 1 | 1992 | 340 | 0.070 |
Why?
|
| Health Care Surveys | 1 | 2007 | 67 | 0.070 |
Why?
|
| Neoplasms | 2 | 2007 | 750 | 0.070 |
Why?
|
| Demography | 1 | 2007 | 91 | 0.070 |
Why?
|
| Diagnosis, Differential | 1 | 2008 | 367 | 0.070 |
Why?
|
| Carbamazepine | 1 | 2006 | 3 | 0.070 |
Why?
|
| Anticonvulsants | 1 | 2006 | 19 | 0.070 |
Why?
|
| Neurons, Afferent | 1 | 2006 | 64 | 0.070 |
Why?
|
| Respiratory Mechanics | 1 | 2006 | 16 | 0.070 |
Why?
|
| Anesthetics, Intravenous | 1 | 2006 | 14 | 0.070 |
Why?
|
| Ventilation-Perfusion Ratio | 1 | 2006 | 12 | 0.070 |
Why?
|
| Leukemia-Lymphoma, Adult T-Cell | 1 | 2006 | 3 | 0.070 |
Why?
|
| Fentanyl | 1 | 2006 | 31 | 0.070 |
Why?
|
| Fatal Outcome | 1 | 2006 | 66 | 0.070 |
Why?
|
| Methemoglobin | 1 | 2005 | 3 | 0.070 |
Why?
|
| Oximetry | 1 | 2005 | 10 | 0.070 |
Why?
|
| Bone Marrow | 1 | 2006 | 76 | 0.060 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 58 | 0.060 |
Why?
|
| Lymphatic Vessels | 1 | 2005 | 17 | 0.060 |
Why?
|
| Pulmonary Artery | 1 | 2006 | 68 | 0.060 |
Why?
|
| Hypoxia | 1 | 2006 | 85 | 0.060 |
Why?
|
| Stress, Psychological | 1 | 2007 | 209 | 0.060 |
Why?
|
| Radiotherapy | 1 | 2004 | 39 | 0.060 |
Why?
|
| Neuromuscular Blockade | 1 | 2024 | 8 | 0.060 |
Why?
|
| Neurons | 1 | 2006 | 275 | 0.060 |
Why?
|
| Interpersonal Relations | 1 | 2004 | 64 | 0.060 |
Why?
|
| Social Support | 1 | 2004 | 122 | 0.060 |
Why?
|
| Brain Neoplasms | 2 | 2000 | 288 | 0.060 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2006 | 465 | 0.050 |
Why?
|
| Risk Factors | 1 | 2008 | 2006 | 0.050 |
Why?
|
| Depression | 1 | 2004 | 210 | 0.050 |
Why?
|
| Epidural Space | 1 | 2022 | 10 | 0.050 |
Why?
|
| Needles | 1 | 2022 | 26 | 0.050 |
Why?
|
| Vincristine | 1 | 2002 | 9 | 0.050 |
Why?
|
| Cardiovascular Diseases | 1 | 2006 | 346 | 0.050 |
Why?
|
| Vocal Cord Paralysis | 1 | 2002 | 5 | 0.050 |
Why?
|
| Bupivacaine | 1 | 2021 | 4 | 0.050 |
Why?
|
| United States | 1 | 2007 | 2031 | 0.050 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2002 | 52 | 0.050 |
Why?
|
| Tomography, Optical Coherence | 1 | 2022 | 89 | 0.050 |
Why?
|
| Swine | 1 | 2022 | 220 | 0.050 |
Why?
|
| Animals | 5 | 2022 | 9957 | 0.050 |
Why?
|
| Restraint, Physical | 1 | 2000 | 12 | 0.050 |
Why?
|
| Liposomes | 1 | 2021 | 142 | 0.040 |
Why?
|
| Thrombocytopenia | 1 | 2000 | 113 | 0.040 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2006 | 586 | 0.040 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2000 | 245 | 0.040 |
Why?
|
| Torpedo | 2 | 1995 | 2 | 0.040 |
Why?
|
| NAV1.8 Voltage-Gated Sodium Channel | 2 | 2006 | 3 | 0.030 |
Why?
|
| Tetrodotoxin | 2 | 2006 | 12 | 0.030 |
Why?
|
| Octanols | 1 | 1995 | 2 | 0.030 |
Why?
|
| Nicotinic Antagonists | 1 | 1995 | 3 | 0.030 |
Why?
|
| Alcohols | 1 | 1995 | 11 | 0.030 |
Why?
|
| Ion Channels | 1 | 1995 | 22 | 0.030 |
Why?
|
| Rats, Sprague-Dawley | 2 | 2006 | 545 | 0.030 |
Why?
|
| Molecular Conformation | 1 | 1993 | 66 | 0.030 |
Why?
|
| Infusions, Intravenous | 1 | 1993 | 99 | 0.030 |
Why?
|
| Rats | 2 | 2006 | 1545 | 0.030 |
Why?
|
| Tubocurarine | 1 | 1992 | 1 | 0.030 |
Why?
|
| Anesthesia Recovery Period | 1 | 1992 | 2 | 0.030 |
Why?
|
| Hospitals, University | 1 | 2012 | 26 | 0.020 |
Why?
|
| Rectal Neoplasms | 1 | 1992 | 9 | 0.020 |
Why?
|
| Body Temperature Regulation | 1 | 2012 | 12 | 0.020 |
Why?
|
| Body Temperature | 1 | 2012 | 30 | 0.020 |
Why?
|
| Neuromuscular Junction | 1 | 1992 | 21 | 0.020 |
Why?
|
| Injections, Spinal | 2 | 2002 | 7 | 0.020 |
Why?
|
| Neoplasms, Multiple Primary | 1 | 1992 | 27 | 0.020 |
Why?
|
| Remission Induction | 2 | 2002 | 50 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 1992 | 253 | 0.020 |
Why?
|
| Platelet Count | 2 | 2002 | 112 | 0.020 |
Why?
|
| Adenocarcinoma | 1 | 1992 | 284 | 0.020 |
Why?
|
| Psychology | 1 | 2007 | 19 | 0.020 |
Why?
|
| Electric Capacitance | 1 | 2006 | 2 | 0.020 |
Why?
|
| Sodium Channel Blockers | 1 | 2006 | 11 | 0.020 |
Why?
|
| Patch-Clamp Techniques | 1 | 2006 | 30 | 0.020 |
Why?
|
| Membrane Potentials | 1 | 2006 | 61 | 0.020 |
Why?
|
| Nociceptors | 1 | 2006 | 42 | 0.020 |
Why?
|
| Bronchial Spasm | 1 | 1986 | 2 | 0.020 |
Why?
|
| Extracorporeal Circulation | 1 | 1986 | 3 | 0.020 |
Why?
|
| Complement C3 | 1 | 1986 | 21 | 0.020 |
Why?
|
| Action Potentials | 1 | 2006 | 194 | 0.020 |
Why?
|
| Antineoplastic Agents | 2 | 2002 | 657 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2007 | 472 | 0.020 |
Why?
|
| Pain Threshold | 1 | 2006 | 89 | 0.020 |
Why?
|
| Retrospective Studies | 2 | 2002 | 2429 | 0.020 |
Why?
|
| Pain | 1 | 2006 | 252 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2006 | 970 | 0.010 |
Why?
|
| Risk | 1 | 2002 | 133 | 0.010 |
Why?
|
| Aged | 1 | 1992 | 5159 | 0.010 |
Why?
|
| Physics | 1 | 2000 | 1 | 0.010 |
Why?
|
| Physical Phenomena | 1 | 2000 | 1 | 0.010 |
Why?
|
| Platelet Transfusion | 1 | 2000 | 29 | 0.010 |
Why?
|
| African Americans | 1 | 2002 | 350 | 0.010 |
Why?
|
| Radiography | 1 | 2000 | 200 | 0.010 |
Why?
|
| Hemorrhage | 1 | 2000 | 259 | 0.010 |
Why?
|
| Heptanol | 1 | 1995 | 1 | 0.010 |
Why?
|
| 1-Octanol | 1 | 1995 | 1 | 0.010 |
Why?
|
| Procaine | 1 | 1995 | 2 | 0.010 |
Why?
|
| Anesthetics | 1 | 1995 | 9 | 0.010 |
Why?
|
| Receptors, Nicotinic | 1 | 1995 | 10 | 0.010 |
Why?
|
| Acetylcholine | 1 | 1995 | 73 | 0.010 |
Why?
|
| Drug Synergism | 1 | 1995 | 100 | 0.010 |
Why?
|
| Binding Sites | 1 | 1995 | 338 | 0.010 |
Why?
|
| Kinetics | 1 | 1995 | 538 | 0.010 |
Why?
|
| Complement C4a | 1 | 1986 | 3 | 0.000 |
Why?
|
| Complement C5a | 1 | 1986 | 5 | 0.000 |
Why?
|
| Complement C5 | 1 | 1986 | 4 | 0.000 |
Why?
|
| Complement C3a | 1 | 1986 | 6 | 0.000 |
Why?
|
| Intraoperative Period | 1 | 1986 | 21 | 0.000 |
Why?
|
| Complement C4 | 1 | 1986 | 16 | 0.000 |
Why?
|
| Complement Activation | 1 | 1986 | 25 | 0.000 |
Why?
|
| Coronary Artery Bypass | 1 | 1986 | 66 | 0.000 |
Why?
|
| Middle Aged | 1 | 1986 | 6813 | 0.000 |
Why?
|